- Ferring will deliver 11 presentations at the virtual congress; including six oral presentations
- The new data being presented further underscores Ferring's commitment to supporting personalized fertility options to help people build families worldwide
Ferring Pharmaceuticals (US) today announced that it will present eleven company-sponsored abstracts, including six oral presentations, at the American Society for Reproductive Medicine (ASRM) 2020 Virtual Scientific Congress & Expo taking place October 17-20, 2020.
"We look forward to presenting data at this year's ASRM congress, where leaders will gather virtually to share meaningful research that advances scientific knowledge in the field of reproductive medicine," said Gaurang Daftary, M.D., M.B.A, Vice President, Reproductive Medicine and Maternal Health at Ferring Pharmaceuticals. "At Ferring, we are committed to addressing the medical needs of patients through the advancement of science. Our presence at ASRM this year underscores that commitment."
Ferring's first oral presentation highlights data from a clinical trial involving infertile women with primary hypothalamic amenorrhea, a rare patient population that is unable to ovulate and achieve pregnancy due to deficiencies in their brain's production or secretion of a key peptide called Gonadotropin Releasing Hormone (GnRH).
Additionally, the company will present three new sub analyses of data from the recently published MEGASET-HR trial. The first abstract characterizes differences in ovarian response dependent upon the type of gonadotropin used and baseline levels of anti-Müllerian Hormone (AMH), a marker of ovarian reserve. The second presents a possible relationship between serum levels of human chorionic gonadotropin (hCG) at the end of stimulation and live birth. The third abstract from the MEGASET-HR trial describes outcomes from the transfer of fresh or frozen embryos designated as normal based on assessment of the number of chromosomes.
The details of all Ferring abstracts presented at the meeting are as follows:
Oral (O-33):
Title: Pulsatile Gonadotropin Releasing Hormone (GnRH) via Subcutaneous Pump for the Treatment of Primary Amenorrhea Associated with Hypogonadotropic Hypogonadism
Date and Time: Saturday, October 17, 2020; 2:30 PM-2:45 PM
Oral (O-169):
Title: Safety evaluation of a novel progesterone vaginal ring (PVR) in luteal phase support: SARA trial results
Date and Time: Monday, October 19, 2020; 1:50 PM-2:05 PM
Oral (O-223):
Title: Differential Ovarian Response to Gonadotropin Preparations Despite Similar Ovarian Reserve: MENOPUR in GnRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) Trial Analysis
Date and Time: Tuesday, October 20, 2020; 1:50 PM-2:05 PM
Oral (O-224):
Title: Serum gonadotropin association with live birth in high-responders undergoing ovarian stimulation: MENOPUR in Gonadotropin Releasing Hormone (GNRH) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) trial analysis
Date and Time: Tuesday, October 20, 2020; 2:05 PM-2:20 PM
Oral (O-225):
Title: Fresh versus frozen euploid blastocyst transfer outcomes in predicted high-responders: MENOPUR in GNRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) trial analysis
Date and Time: Tuesday, October 20, 2020; 2:20 PM-2:35 PM
Poster (P-443):
Title: Similar ovarian response with individualized follitropin delta dosing regimen in Japanese and non-Japanese IVF/ICSI patients
Date and Time: Monday, October 19, 2020; 4:30 PM-6:00 PM
Poster (P-591):
Title: Atosiban and Barusiban improved impaired endometrial blood flow in pregnant rabbits
Date and Time: Monday, October 19, 2020; 4:30 PM-6:00 PM
Poster (P-458):
Title: Similar dose-response profiles for follitropin delta in Japanese and non-Japanese IVF/ICSI patients
Date and Time: Monday, October 19, 2020; 4:30 PM-6:00 PM
Poster (P-560):
Title: Establishing the follitropin delta dose providing compatible ovarian response as 150 IU/ day follitropin alpha for controlled ovarian stimulation
Date and Time: Monday, October 19, 2020; 4:30 PM-6:00 PM
Oral (O-188):
Title: Quinagolide vaginal ring for endometriosis: Results from the clinical Phase 1 program
Date and Time: Tuesday, October 20, 2020; 9:55 AM-10:10 AM
Poster (P-861):
Title: Reduction in OHSS incidence in Japanese IVF/ICSI patients when applying individualized dosing with follitropin delta
Date and Time: Wednesday, October 21, 2020; 3:30 PM-5:00 PM
For more information on the abstracts, visit asrmcongress.org/
Menopur® Indication
Menopur (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in ovulatory patients participating in an Assisted Reproductive Technology (ART) program.
Important Safety Information
Menopur is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.
Menopur should only be used by physicians who are thoroughly familiar with infertility problems. Menopur is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with Menopur. There have been infrequent reports of ovarian neoplasms with Menopur. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with Menopur.
The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.
Please see here for full Prescribing Information.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics. For more information, call 1-888-FERRING + (1-888-337-7464); visit http://www.ferringusa.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005065/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
